Liuwei Huanglong Powder Veterinary Grade API is supplied as a non-sterile, multi-component botanical powder intended for further manufacture into veterinary tablets, injections, capsules, powders, granules, premixes, and solutions. The name indicates a six-ingredient formulation; the exact botanical composition is fixed by the registered formula. The supplier-specific model identifier is recorded on the certificate of analysis and typically distinguishes the particle-size class, drying route, and microbial or endotoxin-control status. No universal pharmacopoeial monograph assigns a single model number across all suppliers, and model codes should not be used to infer equivalence without comparative analytical data. Release specifications are derived from the current registered formula and from compendial powder API controls. Identity is confirmed by high-performance liquid chromatography against authenticated reference materials. The API differs from feed-grade botanical powders in that particle-size distribution, residual moisture, microbial enumeration, elemental impurities, and marker content are controlled before the material is transferred to dosage-form manufacturing.

What Distinguishes a Veterinary-Dosage-Form API from a Milled Botanical Raw Material?

The separation begins at comminution and classification. Raw botanical material often contains fibrous bundles, variable moisture, and a microbial load that is insufficiently controlled for tableting or capsule filling. An API grade is passed through a hammer mill, pin mill, or air-classifier mill and is characterized by laser diffraction in accordance with USP <429>. For tablet and capsule dry blending, the mass-median particle diameter is frequently controlled so that the D90 does not exceed 250 µm; for powder and granule intermediate use, the registered limit may be broader, but sieve distribution must remain consistent across batches. Residual moisture is determined by loss on drying at 105 °C in accordance with USP <731>; botanical powders containing hygroscopic fractions are usually controlled to not more than 5.0% by weight unless stability data support a higher registered limit. Microbial enumeration is performed using USP <61> and USP <62> methods, with typical oral-powder acceptance limits of total aerobic microbial count not more than 10³ CFU/g, total combined yeasts and molds not more than 10² CFU/g, and absence of specified enteric pathogens. Elemental impurities are screened by inductively coupled plasma mass spectrometry under USP <232> and USP <233>.

Quantitative marker analysis provides another release boundary. In a validated HPLC-UV or HPLC-ELSD method, the reversed-phase C18 column may be configured at 250 mm length, 4.6 mm internal diameter, and 5 µm particle size. A flow rate of 1.0 mL/min and column temperature of 30 °C are standard starting conditions. System suitability is expected to show resolution between the critical pair not less than 1.5, tailing factor not more than 2.0, and replicate peak-area RSD not more than 2.0%. These parameters are adjusted according to the validated method and are not product release limits by themselves. Where a Chinese Veterinary Pharmacopoeia monograph exists for the formula, the current edition should be verified for specific identity tests; where no monograph is published, the manufacturer’s validated release method and retained reference standards remain the authoritative basis.

Batch-to-batch consistency is further assessed by marker-content agreement against the registered specification. The API grade is therefore distinguished by laboratory-controlled identity, potency markers, particle size, and microbial load rather than by visual or organoleptic inspection alone. Veterinary APIs face species-specific elemental impurity limits because the same drug can be administered to short-lived poultry or long-lived equines. The registrant derives limits from the maximum daily dose, residual feed intake, and duration-of-use interval using the principles of USP <232> and USP <233>. Analysis by ICP-MS provides quantitative data for arsenic, cadmium, lead, and mercury whether or not the raw botanical sources are grown in mineral-rich soils. No single numeric elemental limit can be stated for all species and routes; the registered product specification is the only authoritative limit.

In tableting and encapsulation operations, the powder is dry-blended with microcrystalline cellulose, croscarmellose sodium, and magnesium stearate; the blend is compressed on a rotary tablet press or filled into hard capsules. Weight variation on a 10-station rotary press with 8 mm standard concave tooling is directly influenced by bulk density and flow. Bulk and tapped densities are measured in accordance with USP <616>; a Hausner ratio above 1.25 and a Carr index above 25% generally indicate marginal flow and may require wet granulation or glidant adjustment. When direct compression is feasible, the API is typically blended in a 500 L ribbon blender or equivalent convective mixer, with blend uniformity confirmed by sampling at least 10 locations and analyzing marker content; the mean result is expected to fall within 90.0–110.0% of target with a relative standard deviation not more than 5.0% unless the registered dossier specifies tighter acceptance criteria. Compression force may range between 10 kN and 30 kN depending on hardness target, with hardness measured by a diametral crushing tester and often specified as not less than 50 N for immediate-release veterinary tablets. Content uniformity is evaluated according to USP <905> with an acceptance value not more than 15.0. Disintegration testing per USP <701> is a finished-product release test, not an API test.

For granulation, purified water, starch paste, or povidone solution is added under high-shear or fluid-bed conditions. A fluid-bed dryer inlet air temperature between 50 °C and 60 °C is a standard starting point for botanical granulations, with thermal degradation of marker compounds monitored by a stability-indicating HPLC method. Granulate bulk density after drying commonly falls between 0.45 g/cm³ and 0.65 g/cm³; the granulate is then milled through a 1.0 mm screen. Fines below 75 µm are often limited to avoid dusting and segregation. Capsule filling on an intermittent-motion dosator machine is sensitive to bulk density variation; if the angle of repose exceeds 40°, mechanical agitation or granulation is introduced. Capsule fill-weight variation is typically controlled to not more than ±5.0% for botanical powders, with final acceptance confirmed by content uniformity testing. Published data for this specific product configuration is limited; therefore the downstream formulator should confirm the effect of milling, drying, and lubricant addition on marker content before release.

Granules and premixes share a requirement for low dust generation and homogeneous distribution in dry feeds. The API is preblended with a compatible carrier—lactose monohydrate, maize starch, or precipitated calcium carbonate—before being diluted into the final premix. Blend uniformity is verified with a thief sampler and marker-content analysis at 10 sampling points; the finished premix is expected to show a coefficient of variation not more than 5.0% for the marker before it is added to the feed mixing line. On a production-scale feed mill, the API premix is added to a horizontal ribbon mixer of 1,000 kg capacity. Marker recovery is checked at 10–20 sampling points. If the bulk density difference between the API and the carrier exceeds 20%, segregation risk increases and an intermediate pocket preblend is used before final dilution. If the premix is steam-conditioned before pelleting, the thermal stability of the marker components at 80–85 °C must be confirmed, because steam conditioning may degrade thermally labile botanical constituents. These processing controls apply specifically to solid oral and feed-directed uses and are not sufficient for injectable solution manufacture.

When the Same Powder Is Redirected to Solution and Injection Manufacturing

Solution manufacture begins with dispersion or extraction of the API in purified water under controlled temperature and agitation. The resulting liquid is checked for pH in accordance with USP <791> and viscosity where the formula contains suspending agents. Oral solutions can tolerate a wider particle-size distribution and higher microbial load than injectable solutions, but the finished product must still meet the microbial limits applicable to oral liquids. For injectable preparations, the conversion route changes fundamentally: the non-sterile API is not injected directly. An injectable solution is prepared from a purified extract or is sterile-filtered through a 0.45 µm clarification membrane followed by a 0.22 µm sterilizing-grade filter under aseptic conditions. The pressure differential across the 0.22 µm membrane should not exceed the manufacturer-rated limit, commonly between 2.0 bar and 4.0 bar for polyvinylidene fluoride membranes. Filter compatibility is tested with the actual formulation because botanical extracts can contain saponins and tannins that bind to nylon or polyethersulfone. If extractables or adsorption exceed the target marker recovery range of 90.0–110.0%, an alternative membrane or a depth-filter pretreatment is required.

The bacterial endotoxin limit is derived from the maximum intended dose in the target species and is quantified by the limulus amebocyte lysate method in USP <85>; no single universal endotoxin limit applies to all veterinary presentations. Method suitability is demonstrated by challenge recovery of 50–200% of the test organisms. Finished injectable solutions also require particulate matter testing as specified in USP <788>, and the container-closure system must protect the formulation from light and moisture. A powder acceptable for oral premix may have total aerobic microbial count up to 10³ CFU/g, but an injection-grade precursor must be subject to additional cleaning, milling, and filtration steps. The API supplier’s low-endotoxin grade is recommended when the downstream user intends to manufacture injectables; otherwise the purification train may be undersized for the required pyrogen reduction.

Relative to common alternative materials, the API grade differs from spray-dried extracts in that it retains the native multi-component matrix rather than a concentrated extract. It differs from standard herbal premixes in that release includes compendial test methods and marker quantification. It differs from a terminal-sterilized powder for injection in that it is supplied non-sterile and requires downstream filtration and aseptic processing. Storage is maintained in sealed, light-resistant containers at controlled room temperature 20–25 °C in accordance with USP <659> unless the registered specification states otherwise. The API is packed in double-layer low-density polyethylene bags inside a sealed aluminum-laminated outer bag or fiber drum. Desiccant is inserted when the moisture specification is below 5.0%. After opening, the material should be re-sealed under nitrogen if the residual moisture specification indicates a hygroscopic fraction; re-testing of loss on drying and microbial enumeration is required after 30 days of open storage unless the stability protocol provides longer data. Batch-to-batch comparability for injectable solutions should be demonstrated by comparative particle-size, assay, related substances, and endotoxin data before a new API lot is introduced into validated manufacturing.